SYRA / Syra Health Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41822 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of i

SYRA HEALTH CORP. CONDENSED BALANCE SHEETS

Exhibit 99.1 Syra Health Announces Second Quarter Financial Results, Advancing Toward Profitability on Margin Gains and Cost Reductions - Revenue of $1.9 Million consistent with the year-ago period - Revenue led by Population Health’s growth up 197% compared to Q2 2024 - Gross Margin increases to 38.7%, up 2,090 basis points compared to Q2 2024 - Earnings per share for the second quarter of 2025 w

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of inc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of inc

Syra Health Board Begins CEO Search to Drive Growth

Exhibit 99.1 Syra Health Board Begins CEO Search to Drive Growth Carmel, Ind., May 20, 2025 /PRNewswire/ – Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 SYRA HEALTH CORP. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 SYRA HEALTH CORP. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41822 SYRA HEALTH CORP.

SYRA HEALTH CORP. BALANCE SHEETS

Exhibit 99.1 Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY Revenue increase led by Population Health’s 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET Carmel, Ind., May 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-41822 SYRA HEALTH CORP. T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-41822 SYRA HEALTH CORP. The Nasdaq Capital Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 1119 Keys

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of inc

SYRA HEALTH CORP. BALANCE SHEETS

Exhibit 99.1 Syra Health Announces Full-Year Revenue of $8.0 Million, Up 45% YoY 2024 Population Health Revenue Acceleration to 132% YoY Q4 2024 Net Losses Cut Nearly in Half Compared to Q4 2023, Highlighting Major Efficiency Gains Continued Momentum with New Customer Wins and Contract Extensions Driving Sustainable Growth A conference call will be held today, Tuesday, March 11 at 9:00 am ET Carme

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number 001-41822 SYRA HEALTH CORP. (Exact Name of

Insider Trading Policy

Exhibit 19.1 SYRA HEALTH CORP. INSIDER TRADING POLICY (EFFECTIVE OCTOBER 3, 2023) This Insider Trading Policy (the “Policy”) provides guidelines to employees, officers, directors and consultants and their respective Family Members and Controlled Entities (as defined herein) (collectively, “Covered Individuals” or “you”) of Syra Health Corp. (“Syra”, or “we”) regarding transactions in Syra’s securi

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032 February 6, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jenna Hough Re: Syra Health Corp. Registration Statement on Form S-1 Filed January 24, 2025 File No. 333-284498 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securiti

As filed with the Securities and Exchange Commission on February 5, 2025

As filed with the Securities and Exchange Commission on February 5, 2025 Registration Statement No.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) SYRA HEALTH CORP.

Form of Senior Indenture

Exhibit 4.3 SYRA HEALTH CORP., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.1 Designation and Terms of Securities 3 Section 2.2 Form of Securities and Trustee’s Certificate 5 Section

As filed with the Securities and Exchange Commission on January 24, 2025

As filed with the Securities and Exchange Commission on January 24, 2025 Registration Statement No.

Form of Subordinated Indenture

Exhibit 4.4 SYRA HEALTH CORP., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 SYRA HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 SYRA HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of

Syra Health Delivers Third Quarter 2024 Financial Results Achieved Net Revenue of $2.3 million, ~42% Growth Over the Prior Year Quarter Gross Margins Increased Following Shift in Operational Strategy Net Loss Narrowed to $417,535 ($0.06 per share), a

Exhibit 99.1 Syra Health Delivers Third Quarter 2024 Financial Results Achieved Net Revenue of $2.3 million, ~42% Growth Over the Prior Year Quarter Gross Margins Increased Following Shift in Operational Strategy Net Loss Narrowed to $417,535 ($0.06 per share), a Significant Improvement from the $1.39 million ($0.21 per share) Net Loss in Q2 of 2024 Aiming to Attain Profitability in 2025 through T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41822 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 SYRA HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 SYRA HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of

3,203,125 Shares of Class A Common Stock Series A Warrants to Purchase up to 3,203,125 Shares of Class A Common Stock Series B Warrants to Purchase up to 3,203,125 Shares of Class A Common Stock Placement Agent Warrants to Purchase up to 160,156 Shar

Filed Pursuant to Rule 424(b)(4) Registration No. 333-281583 Prospectus 3,203,125 Shares of Class A Common Stock Series A Warrants to Purchase up to 3,203,125 Shares of Class A Common Stock Series B Warrants to Purchase up to 3,203,125 Shares of Class A Common Stock Placement Agent Warrants to Purchase up to 160,156 Shares of Class A Common Stock Up to 6,566,406 Shares of Class A Common Stock Unde

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032 September 9, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Rucha Pandit Re: Syra Health Corp. Registration Statement on Form S-1 Filed August 15, 2024 File No. 333-281583 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securit

September 9, 2024

September 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Syra Health Corp. Registration Statement on Form S-1 (File No. 333-281583) – Concurrence in Acceleration Request Ladies and Gentlemen: Rodman & Renshaw LLC (“Rodman”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statemen

Form of Restricted Stock Award Agreement pursuant to Syra Health Corp. 2022 Omnibus Equity Incentive Plan

Exhibit 10.20 SYRA HEALTH CORP. RESTRICTED STOCK Award NOTICE (2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Syra Health Corp. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted a Restricted Stock award. Thi

Form of Restricted Stock Unit Award Agreement pursuant to Syra Health Corp. 2022 Omnibus Equity Incentive Plan

Exhibit 10.21 SYRA HEALTH CORP. RESTRICTED STOCK UNIT AWARD GRANT NOTICE (2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Syra Health Corp. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted a Restricted Stock

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of i

Form of Series B Warrant

Exhibit 4.3 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT SYRA HEALTH CORP. Warrant Shares: Issue Date:, 2024 Initial Exercise Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af

Form of Securities Purchase Agreement

Exhibit 10.22 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between Syra Health Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Syra Health Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Am

Form of Option Agreement pursuant to Syra Health Corp. 2022 Omnibus Equity Incentive Plan

Exhibit 10.19 SYRA HEALTH CORP. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Syra Health Corp. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted an option to

As filed with the Securities and Exchange Commission on August 15, 2024

As filed with the Securities and Exchange Commission on August 15, 2024 Registration Statement No.

Form of Placement Agent Warrant

Exhibit 4.5 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT SYRA HEALTH CORP. Warrant Shares: Issue Date:, 2024 Initial Exercise Date: , 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any

Form of Pre-Funded Warrant

Exhibit 4.4 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT SYRA HEALTH CORP. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Commercial Lease Addendum by and between the Company and STVentures LLC

Exhibit 10.23 COMMERCIAL LEASE ADDENDUM This Addendum to the Commercial Lease Agreement (this “Agreement”) is made this 1st day of July 2024 by and between STVentures LLC, an entity located at 1119 Keystone Way, Carmel, IN 46032 (“Landlord”) and Syra Health Corp, an entity located at 1119 Keystone Way, Suite 201, Carmel, IN 46032 (“Tenant”) relating to the renewal of the Commercial Lease Agreement

Form of Series A Warrant

Exhibit 4.2 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT SYRA HEALTH CORP. Warrant Shares:   Issue Date:, 2024 Initial Exercise Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Syra Health Announces Second Quarter 2024 Financial Results, Led by Strong Revenue Growth of 101% Conference call will be held today, Thursday, August 8 at 9:00 am ET

Exhibit 99.1 Syra Health Announces Second Quarter 2024 Financial Results, Led by Strong Revenue Growth of 101% Conference call will be held today, Thursday, August 8 at 9:00 am ET Carmel, IN, August 8, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare technology company powering better health by providing meaningful solutions, announced today its fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41822 SYRA HEALTH CORP.

As confidentially submitted to the U.S. Securities and Exchange Commission on July [ ], 2024. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission, and all information herein remains strictly

As confidentially submitted to the U.S. Securities and Exchange Commission on July [ ], 2024. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission, and all information herein remains strictly confidential. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 SYRA HEALTH CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41822 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SYRA HEALTH CORP. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of incor

Syra Health Announces First Quarter 2024 Financial Results, Led By Strong Revenue Growth of 47%. Conference call will be held today, Thursday, May 9 at 9:00 am ET

Exhibit 99.1 Syra Health Announces First Quarter 2024 Financial Results, Led By Strong Revenue Growth of 47%. Conference call will be held today, Thursday, May 9 at 9:00 am ET Carmel, IN, May 9, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare technology company with a mission to improve healthcare by providing innovative services and technology so

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of in

Clawback Policy

Exhibit 97.1 Syra Health Corp. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this Clawback

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 DESCRIPTION OF SECURITIES Class A Common Stock and Class B Common Stock We have authorized Class A common stock and Class B common stock. Dividend Rights Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our Class A common stock and Class B common stock are entitled to share equally, identically, and ratably, on a per share b

Syra Health Announces Fourth-Quarter and Full-Year 2023 Financial Results. Projects 2024 Revenue Growth of 64% to 100%. Conference call will be held today, Monday, March 25 at 9:00am ET

Exhibit 99.1 Syra Health Announces Fourth-Quarter and Full-Year 2023 Financial Results. Projects 2024 Revenue Growth of 64% to 100%. Conference call will be held today, Monday, March 25 at 9:00am ET Carmel, IN, March 25, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare consulting company with a mission to improve healthcare by providing innovative

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 SYRA HEALTH CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number 001-41822 SYRA HEALTH CORP. (Exact Name of

SYRA / Syra Health Corp. / McAleer Mike Edward Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Syra Health Corp (Name of Issuer) Class A Common Stock (Title of Class of Securities) 87168W203 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 8, 2024 (Date of

SYRA / Syra Health Corp. / Stock Loan Solutions LLC Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Syra Health Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 87168W203 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 8, 2024 (

SYRA / Syra Health Corp. / Stock Loan Solutions LLC Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Syra Health Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 87168W203 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 24, 2024 (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41822 SYRA HEALTH CORP.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction of incorporation) (Commission Fil

Syra Health Announces Third Quarter 2023 Financial Results Conference call will be held today, Tuesday, November 14 at 9:00am ET

Exhibit 99.1 Syra Health Announces Third Quarter 2023 Financial Results Conference call will be held today, Tuesday, November 14 at 9:00am ET Carmel, IN, November 14, 2023 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare company addressing some of healthcare’s most significant challenges by providing innovative services and technology solutions, today a

SYRA / Syra Health Corp. / McAleer Mike Edward Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Syra Health Corp. (Name of Issuer) (Title of Class of Securities) 87168W203 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 29th, 2023 (Date of Event which Requires Filing of this St

Stock Loan Solutions LLC

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Syra Health Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 87168W203 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 6, 2023 (Date of

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) SYRA HEALTH CORP.

As filed with the Securities and Exchange Commission on October 6, 2023

As filed with the Securities and Exchange Commission on October 6, 2023  Registration No.

Syra Health Corp. Announces Pricing of Upsized Initial Public Offering

Exhibit 99.1 Syra Health Corp. Announces Pricing of Upsized Initial Public Offering CARMEL, IN, September 29, 2023 /PRNewswire/ — Syra Health Corp. (NASDAQ: SYRA) (“Syra Health” or the “Company”), a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the pricing of its upsized initial public offering (the “IP

Amended and Restated Bylaws of Syra Health Corp.

Exhibit 3.1 AMENDED AND RESTATED BYLAWS of SYRA HEALTH CORP. As Adopted October 3, 2023 ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Syra Health Corp. (the “Corporation”), shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “certificate of incorporation”). 1.2 OTHER OFFICES. The Corporation’s board of

Syra Health Corp. Announces Closing of Initial Public Offering

Exhibit 99.2 Syra Health Corp. Announces Closing of Initial Public Offering CARMEL, Ind., October 3, 2023 /PRNewswire/ — Syra Health Corp. (NASDAQ: SYRA) (“Syra Health” or the “Company”), a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the closing of its upsized initial public offering (the “IPO”) of 1,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 001-41822 85-4027995 (State or other jurisdiction (Commission (I. R. S. Employer o

1,615,000 Units Shares of Class A Common Stock and Warrants Syra Health Corp.

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-271622 333-274754 1,615,000 Units Shares of Class A Common Stock and Warrants Syra Health Corp. This is the initial public offering of units of securities (the “Units”) of Syra Health Corp. Prior to this offering, there has been no public market for shares of our Class A common stock. The public offering price per Unit is $4.125. Ea

September 28, 2023

September 28, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F.

As filed with the U.S. Securities and Exchange Commission on September 28, 2023

As filed with the U.S. Securities and Exchange Commission on September 28, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction of incorporation or orga

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) SYRA HEALTH CORP.

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 85-4027995 (State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) 1119

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032 September 28, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attn: Scott Stringer Joel Parker Brian Fetterolf Erin Jaskot Re: Syra Health Corp. Registration Statement on Form S-1, as amended File No. 333-271622 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regu

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032 September 27, 2023

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032 September 27, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attn: Scott Stringer Joel Parker Brian Fetterolf Erin Jaskot Re: Syra Health Corp. Registration Statement on Form S-1, as amended File No. 333-271622 Ladies and Gentlemen: Syra Health Corp. (the “Company”) hereby respectfu

September 27, 2023

September 27, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F.

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032

SYRA HEALTH CORP. 1119 Keystone Way N. #201 Carmel, IN 46032 September 22, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attn: Scott Stringer Joel Parker Brian Fetterolf Erin Jaskot Re: Syra Health Corp. Registration Statement on Form S-1, as amended File No. 333-271622 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regu

[Signature Page Follows]

September 22, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F.

As filed with the U.S. Securities and Exchange Commission on September 13, 2023

As filed with the U.S. Securities and Exchange Commission on September 13, 2023 Registration Statement No. 333-271622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 5 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

FWP

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) SYRA HEALTH CORP.

Modification of Loan Agreement by and between the Company and Citizens State Bank of New Castle dated August 24, 2023

Exhibit 10.29 MODIFICATION OF LOAN AGREEMENT At the request of Syra Health Corp Borrower (s) and by mutual agreement of the parties, the terms of Commercial Loan number 709505950 for $ 800,000.00 dated the 07 day of February , 2022 , made by the Citizens State Bank of New Castle, Indiana to, or assumed by, the undersigned borrower (s) are hereby modified in the following particulars and the maturi

Amendment to Amended and Restated Certificate of Incorporation dated August 28, 2023 (Incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)

Exhibit 3.6

Syra Health Corp. 2022 Omnibus Equity Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)

Exhibit 10.5 SYRA HEALTH CORP. 2022 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Syra Health Corp. 2022 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth

Form of Underwriting Agreement

Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2023 Kingswood, a division of Kingswood Capital Partners, LLC 7280 W. Palmetto Park Rd. Suite 301 Boca Raton, FL 33433 As Representative of the Underwriters named on Annex A hereto Ladies and Gentlemen: The undersigned, Syra Health Corp., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters na

As filed with the U.S. Securities and Exchange Commission on September 5, 2023

As filed with the U.S. Securities and Exchange Commission on September 5, 2023 Registration Statement No. 333-271622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 4 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction

As filed with the U.S. Securities and Exchange Commission on July 17, 2023

As filed with the U.S. Securities and Exchange Commission on July 17, 2023 Registration Statement No. 333-271622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction of i

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) SYRA HEALTH CORP.

Promissory Note by and between the Company and Citizens State Bank of New Castle dated May 22, 2023

Exhibit 10.28 PROMISSORY NOTE Principal $800,000 00 Loan Date 05-22-2023 Maturity 08-22-2023 Loan No. 709505950 Call /Col 4A / 012 Account S9070940 Officer MMA Initials MCM References in the boxes above are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing “***” has been omitted due to text length limitations. Borrow

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

As filed with the U.S. Securities and Exchange Commission on July 6, 2023

As filed with the U.S. Securities and Exchange Commission on July 6, 2023 Registration Statement No. 333-271622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction of in

Form of Representative’s Unit Purchase Option

Exhibit 4.2 THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION OR CAUSE IT TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CA

Form of Underwriting Agreement

Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2023 Kingswood, a division of Kingswood Capital Partners, LLC 7280 W. Palmetto Park Rd. Suite 301 Boca Raton, FL 33433 As Representative of the Underwriters named on Annex A hereto Ladies and Gentlemen: The undersigned, Syra Health Corp., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters na

Commercial Security Agreement by and between the Company and Citizens State Bank of New Castle dated May 22, 2023

Exhibit 10.27 COMMERCIAL SECURITY AGREEMENT Principal $800,000.00 Loan Date 05-22-2023 Maturity 08-22-2023 Loan No 709505950 Call / Coll 4A / 012 Account S9070940 Officer MMA Initials MCM References in the boxes above are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing “• • •” has been omitted due to text length li

Business Loan Agreement by and between the Company and Citizens State Bank of New Castle dated May 22, 2023

Exhibit 10.26 *000000000709505950007005222023085-4027995NEW* BUSINESS LOAN AGREEMENT Principal $800,000.00 Loan Date 05-22-2023 Maturity 08-22-2023 Loan No. 709505950 Call / Coll 4A / 012 Account S9070940 Officer MMA Initials MCM References in the boxes above are for Lender’s use only and do not limit the applicability of this document to any particular loan or Item. Any item above containing “* *

Letter from Friedman LLP

Exhibit 16.1 June 12, 2023 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by Syra Health Corp. under the section entitled “Changes in and Disagreements with Accountants on Accounting and Financial Disclosure” of its Form S-1 dated June 12, 2023. We agree with the statements concerning our Firm in such Form S-1; we are not

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) SYRA HEALTH CORP.

FWP

Amendment to Amended and Restated Certificate of Incorporation dated May 30, 2023 (Incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)

Exhibit 3.3

As filed with the U.S. Securities and Exchange Commission on June 12, 2023

As filed with the U.S. Securities and Exchange Commission on June 12, 2023 Registration Statement No. 333-271622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction of i

Form of Subscription Agreement

Exhibit 10.16 [*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY

Form of Warrant Agent Agreement by and between the Company and Pacific Stock Transfer Company (including the terms of the Warrant)

Exhibit 4.3 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [ ] [ ], 2023 (the “Issuance Date”) between Syra Health Corp., a company incorporated under the laws of the State of Delaware (the “Company”), and Pacific Stock Transfer [ ], a [ ] (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”),

Letter of Marcum LLP

Exhibit 16.2 June 12, 2023 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by Syra Health Corp. under the section entitled “Changes in and Disagreements with Accountants on Accounting and Financial Disclosure” of its Form S-1 dated June 12, 2023. We agree with the statements concerning our Firm in such Form S-1; we are not

Form of Convertible Note

Exhibit 10.17 Form of Convertible Promissory Note NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

Amendment No. 2 to Professional Services Contract by and between the Company and Indiana Family and Social Services Administration, NeuroDiagnostic Institute

Exhibit 10.3 AMENDMENT #2 CONTRACT #0000000000000000000055827 This is an Amendment to the Contract (the “Contract”) entered into by and between the Indiana Family and Social Services Administration. NeuroDiagnostic Institute (the “State”) and SYRA HEALTH CORP (the “Contractor”) approved by the last State signatory on April 29, 2022. In consideration of the mutual undertakings and covenants hereina

Consent of Ketan Paranjape, Director Nominee

Exhibit 99.4 CONSENT OF DIRECTOR NOMINEE Syra Health Corp. (the “Company”) is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering (“IPO”) of its Class A common stock. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securit

Consent of Andrew M. Dahlem, Director Nominee

Exhibit 99.2 CONSENT OF DIRECTOR NOMINEE Syra Health Corp. (the “Company”) is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering (“IPO”) of its Class A common stock. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securit

Employment Agreement by and between the Company and Sandeep Allam dated February 29, 2022

Exhibit 10.20 Employment Agreement THIS EMPLOYMENT AGREEMENT is made on this 29 day of February, 2022, by and between SYRA HEALTH, an Indiana Incorporation having its office at 1119 Keystone Way, Suite 201, Carmel, IN 46032 (“SYRA HEALTH”) and Sandeep Allam an individual residing at (“Employee.”) WHEREAS, SYRA HEALTH is in a business of providing innovative solutions and services to myriad of indu

Amendment No. 1 to Professional Services Contract by and between the Company and Indiana Family and Social Services Administration, NeuroDiagnostic Institute

Exhibit 10.2 AMENDMENT #1 CONTRACT #0000000000000000000055827 This is an Amendment to the Contract (the “Contract”) entered into by and between the Indiana Family and Social Services Administration, NeuroDiagnostic Institute (the “State”) and SYRA HEALTH CORP (the “Contractor”) approved by the last State signatory on August 09, 2021. In consideration of the mutual undertakings and covenants herein

Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)

Exhibit 3.4 AMENDED AND RESTATED BYLAWS of SYRA HEALTH CORP. As Adopted [ ] ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Syra Health Corp. (the “Corporation”), shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “certificate of incorporation”). 1.2 OTHER OFFICES. The Corporation’s board of directors (t

Amendment No. 1 to Employment Agreement by and between the Company and Sandeep Allam dated October 18, 2022

Exhibit 10.21 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (this “Amendment”) to the Employment Agreement is dated as of October 18, 2022 and is entered into by and between Syra Health Corp., a Delaware corporation (the “Corporation”), and Sandeep Allam (the “Employee”). All capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Employment

Commercial Security Agreement by and between the Company and Citizens State Bank of New Castle dated February 7, 2022

Exhibit 10.11 COMMERCIAL SECURITY AGREEMENT Principal Loan Date Maturity Loan No. Call / Coll Account Officer Initials $1,500,000.00 02-07-2022 12-31-2022 709505950 4A / 012 S9070940 MAP References in the boxes above are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing ***** has been omitted due to text length limit

Business Loan Agreement by and between the Company and Citizens State Bank of New Castle dated February 7, 2022

Exhibit 10.10 BUSINESS LOAN AGREEMENT Principal Loan Date Maturity Loan No. Call / Coll Account Officer Initials $1,500,000.00 02-07-2022 12-31-2022 709505950 4A / 012 S9070940 MAP References in the boxes above are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing ***** has been omitted due to text length limitations

Professional Services Contract dated as of May 4, 2021 by and between the Company and Indiana Family and Social Services Administration, NeuroDiagnostic Institute

Exhibit 10.1 PROFESSIONAL SERVICES CONTRACT Contract #0000000000000000000055827 This Contract (“Contract”), entered into by and between Indiana Family and Social Services Administration, NeuroDiagnostic Institute (the “State”) and SYRA HEALTH CORP (the “Contractor”), is executed pursuant to the terms and conditions set forth herein. In consideration of those mutual undertakings and covenants, the

STVentures Lease Agreement dated July 1, 2021 by and between the Company and STVentures LLC

EX-10.15 21 ex10-15.htm Exhibit 10.15 COMMERCIAL LEASE AGREEMENT This Commercial Lease Agreement (this “Agreement”) is made this 1st day of July, 2021, by and between STVentures LLC, an entity located at 1119 Keystone Way, Carmel, IN 46032 (“Landlord”) and SYRA Health Corp, an entity located at 1119 Keystone Way, Suite 201, Carmel, IN 46032 (“Tenant”). In consideration of the mutual covenants here

Modification of Loan Agreement by and between the Company and Citizens State Bank of New Castle dated December 16, 2022

Exhibit 10.18 Form of Convertible Promissory Note NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN

Specimen Stock Certificate evidencing the shares of Class A common stock

Exhibit 4.1

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) SYRA HEALTH CORP.

Consent of Sherron Rogers, Director Nominee

Exhibit 99.1 CONSENT OF DIRECTOR NOMINEE Syra Health Corp. (the “Company”) is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering (“IPO”) of its Class A common stock. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securit

Bylaws, currently in effect

Exhibit 3.3 BYLAWS of SYRA HEALTH CORP. As Adopted April 11, 2022 ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Syra Health Corp. (the “Corporation”), shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “certificate of incorporation”). 1.2 OTHER OFFICES. The Corporation’s board of directors (the “Board”

Amended and Restated Certificate of Incorporation, currently in effect

Exhibit 3.1

Amendment No. 3 to Employment Agreement by and between the Company and Deepika Vuppalanchi dated October 18, 2022

Exhibit 10.9 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment (this “Amendment”) to the Employment Agreement is dated as of October 18, 2022 and is entered into by and between Syra Health Corp., a Delaware corporation (the “Corporation”), and Deepika Vuppalanchi (the “Employee”). All capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Employ

Amendment No. 1 to Professional Services Contract dated as of April 25, 2023 by and between the Company and Indiana Family and Social Services Administration, Division of Mental Health and Addiction

Exhibit 10.25 AMENDMENT #1 CONTRACT #0000000000000000000056593 This is an Amendment to the Contract (the “Contract”) entered into by and between the Indiana Family and Social Services Administration, Division of Mental Health and Addiction (the “State”) and SYRA HEALTH CORP (the “Contractor”) approved by the last State signatory on October 6, 2021. In consideration of the mutual undertakings and c

Employment Agreement by and between the Company and Priya Prasad dated February 29, 2022

Exhibit 10.22 Employment Agreement THIS EMPLOYMENT AGREEMENT is made on this 29 day of February, 2022, by and between SYRA HEALTH, an Indiana Incorporation having its office at 1119 Keystone Way, Suite 201, Carmel, IN 46032 (“SYRA HEALTH”) and Priya Prasad an individual residing at (“Employee.”) WHEREAS, SYRA HEALTH is in a business of providing innovative solutions and services to myriad of indus

Professional Services Contract dated as of September 3, 2021 by and between the Company and Indiana Family and Social Services Administration, Division of Mental Health and Addiction

Exhibit 10.13 PROFESSIONAL SERVICES CONTRACT Contract #0000000000000000000056593 This Contract (“Contract”), entered into by and between Indiana Family and Social Services Administration, Division of Mental Health and Addiction (the “State”) and SYRA HEALTH CORP (the “Contractor”), is executed pursuant to the terms and conditions set forth herein. In consideration of those mutual undertakings and

Amendment to Amended and Restated Certificate of Incorporation dated October 6, 2022 (Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)

Exhibit 3.2

Amendment No. 2 to Employment Agreement by and between the Company and Deepika Vuppalanchi dated March 1, 2022

Exhibit 10.8 1119 Keystone Way, Suite #201, Carmel, IN 46032 317-922-0922 Tel 866-896-0246 Fax March 01, 2022 To Deepika Vuppalanchi 13756 Monique Dr. Carmel, Indiana 46074 Subject: Increase in salary Dear Deepika, We would like to express our gratitude by awarding you a salary increase of $301,500 per annum starting from March 01, 2022. Your accomplishments have been integral to our success, and

Employment Agreement by and between the Company and Deepika Vuppalanchi dated April 15, 2021

Exhibit 10.6 Employment Agreement THIS EMPLOYMENT AGREEMENT is made on this 15 day of April, 2021 , by and between SYRA HEALTH, an Indiana Incorporation having its office at 1119 Keystone Way, Suite 101, Carmel, IN 46032 (“SYRA HEALTH”) and /s/ Deepika Vuppalanchi an individual residing at 13756 Monique Dr, Carmel, IN 46074 (“Employee.”) WHEREAS, SYRA HEALTH is in a business of providing innovativ

Amendment No. 1 to Employment Agreement by and between the Company and Priya Prasad dated May 27, 2022

Exhibit 10.23 1119 Keystone Way, Suite 201 Carmel, IN 46032 (317) 922-1112 Tel (888) 614-5409 Fax May 27, 2022 Priya Prasad 25 Magnolia Road Sharon, MA 02067 Subject: Increase in Salary Dear Priya, We are pleased to inform you that you will be receiving an increase in salary based on your request. Effective May 1st, 2022, your salary will increase to $150,000.00 (One Hundred and Fifty Thousand Dol

STVentures Lease Agreement dated July 1, 2021 by and between the Company and STVentures LLC

Exhibit 10.14 VENDOR MASTER SERVICES AGREEMENT This Vendor Master Services Agreement (the “Agreement”) is made as of the 29th day of September, 2021, (the “Effective Date”) between PRECISIONvalue (Chicago), LLC, with an address of 72 West Adams Street, Suite 1200, Chicago, IL 60603 (“Precision”) and SyraHealth, with an office at 1119 Keystone Way N #201, Carmel, IN 46032 (“Vendor”) (with each of P

Promissory Note by and between the Company and Citizens State Bank of New Castle dated February 7, 2022

Exhibit 10.12 PROMISSORY NOTE Principal Loan Date Maturity Loan No Call / Coll Account Officer Initials $1,500,000.00 02-07-2022 12-31-2022 709505950 4A / 012 S9070940 MAP References in the boxes above are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing”***” has been omitted due to text length limitations. Borrower

Form of Convertible Note

Exhibit 10.17 [*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY

Form of Indemnification Agreement for Officers and Directors

Exhibit 10.4 SYRA HEALTH CORP. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [ ], 202[ ] by and between Syra Health Corp., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, hig

As filed with the U.S. Securities and Exchange Commission on May 3, 2023

As filed with the U.S. Securities and Exchange Commission on May 3, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Delaware 7361 85-4027995 (State or other jurisdiction of incorporation or organizatio

Consent of Avutu Reddy, Director Nominee

Exhibit 99.5 CONSENT OF DIRECTOR NOMINEE Syra Health Corp. (the “Company”) is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering (“IPO”) of its Class A common stock. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securit

Syra Health Corp. 2022 Omnibus Equity Incentive Plan

Exhibit 10.5 SYRA HEALTH CORP. 2022 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Syra Health Corp. 2022 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth

Commercial Lease Addendum dated May 1, 2022 by and between the Company and STVentures LLC

Exhibit 10.16 COMMERCIAL LEASE ADDENDUM This Addendum to the Commercial Lease Agreement (this “Agreement”) is made this 1st day of May, 2022, by and between STVentures LLC, an entity located at 1119 Keystone Way, Carmel, IN 46032 (“Landlord”) and Syra Health Corp, an entity located at 1119 Keystone Way, Suite 201, Carmel, IN 46032 (“Tenant”). In consideration of the mutual covenants herein contain

Modification of Loan Agreement by and between the Company and Citizens State Bank of New Castle dated March 8, 2023

Exhibit 10.19 MODIFICATION OF LOAN AGREEMENT At the request of Syra Health Corp Borrower (s) and by mutual agreement of the parties, the terms of Commercial Loan number 709505950 for $ 1,500,000.00 dated the 7th day of February, 2022, made by the Citizens State Bank of New Castle, Indiana to, or assumed by, the undersigned borrower (s) are hereby modified in the following particulars and the matur

Consent of Vijayapal R. Reddy, Director Nominee

Exhibit 99.3 CONSENT OF DIRECTOR NOMINEE Syra Health Corp. (the “Company”) is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering (“IPO”) of its Class A common stock. In connection with the IPO, I hereby consent, pursuant to Rule 438 of the Securit

Amendment No. 1 to Employment Agreement by and between the Company and Deepika Vuppalanchi dated September 1, 2021

Exhibit 10.7 1119 Keystone Way, Suite #201, Carmel, IN 46032 317-922-0922 Tel 866-896-0246 Fax September 01, 2021 To Deepika Vuppalanchi 13756 Monique Dr. Carmel, Indiana 46074 Subject: Increase in salary Dear Deepika, We would like to express our gratitude by awarding you a salary increase of $200,000 per annum starting from August 01, 2021. Your accomplishments have been integral to our success,

Amendment No. 2 to Employment Agreement by and between the Company and Priya Prasad dated October 18, 2022

Exhibit 10.24 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (this “Amendment”) to the Employment Agreement is dated as of October 18, 2022 and is entered into by and between Syra Health Corp., a Delaware corporation (the “Corporation”), and Priya Prasad (the “Employee”). All capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Employment

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

As confidentially submitted to the U.S. Securities and Exchange Commission on January 30, 2023 pursuant to the Jumpstart Our Business Startups Act of 2012

As confidentially submitted to the U.S. Securities and Exchange Commission on January 30, 2023 pursuant to the Jumpstart Our Business Startups Act of 2012 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Del

As confidentially submitted to the U.S. Securities and Exchange Commission on December 14, 2022 pursuant to the Jumpstart Our Business Startups Act of 2012

As confidentially submitted to the U.S. Securities and Exchange Commission on December 14, 2022 pursuant to the Jumpstart Our Business Startups Act of 2012 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) De

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

Sheppard, Mullin, Richter & Hampton LLP

Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

As confidentially submitted to the U.S. Securities and Exchange Commission on November 2, 2022 pursuant to the Jumpstart Our Business Startups Act of 2012

As confidentially submitted to the U.S. Securities and Exchange Commission on November 2, 2022 pursuant to the Jumpstart Our Business Startups Act of 2012 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYRA HEALTH CORP. (Exact name of registrant as specified in its charter) Del